Pranlukast

Drugbox
IUPAC_name = "N"- [4-oxo-2-(2"H"-tetrazol-5-yl)chromen-7-yl] -
4-(4-phenylbutoxy)benzamide

---

CAS_number=
ATC_prefix=R03
ATC_suffix=DC02
PubChem=115100
DrugBank=
C = 27 | H = 23 | N = 5 | O = 4
molecular_weight = 481.503 g/mol
bioavailability=
metabolism = Hepatic (mainly CYP3A4)cite journal | author = Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S | title = Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. | journal = Drug Metab Pharmacokinet | volume = 21 | issue = 2 | pages = 133–9 | year = 2006 | pmid = 16702733 | url = http://www.jstage.jst.go.jp/article/dmpk/21/2/21_133/_article | doi = 10.2133/dmpk.21.133]
elimination_half-life= 1.5 hours
excretion =
pregnancy_category =
legal_status =
routes_of_administration= Oral

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s Singulair (montelukast). It is currently under clinical trials.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective.

References